YOUR RUNDOWN

Scam-y stem cells?

A federal judge sided with the FDA to crack down on unapproved stem cell clinics.

Give me the background on this ruling.

In 2018, the FDA took legal action against a Florida stem cell clinic when three women went blind after receiving intravitreal injections of stem cells from the clinic to treat their AMD. Before the injection, their vision ranged from 20/30 to 20/200, but afterwards they had 20/200 to LP vision. The injection contained stem cells that were obtained from fat removed from their abdomen through liposuction.

Why is the FDA involved?

Because the clinic is essentially making a drug to give to patients and that sort of thing needs to be regulated by the FDA. The clinic however says that because they are using the patients own stem cells, it falls within an exception from FDA regulations for "minimally manipulated" tissues or substance. The federal judge reviewing the case didn't buy it and sided with the FDA. (via)

Goldman Sachs wants to talk eye health

The merchant banking division of Goldman Sachs Group is buying the company Capital Vision Services.

What is Capital Vision Services?

It's also known as MyEyeDr, which operates 575 optometry practices across the nation.

Will Goldman Sachs be running these offices now?

No. Goldman says it made the purchase as an investment, reportedly worth 2.7 billion. A spokesperson from Goldman said that the company looks forward to partnering with Capital Vision Services and its "proven consumer-directed health care model that champions optometrists and promotes eye health."

If you want to learn more about private equity, this podcast can help. (via)

WHAT YOUR PATIENT MIGHT ASK YOU

Are there glasses that can prevent myopia progression?

There is a promising option on the horizon. A research team has collaborated with Hoya on a new spectacle lens called the Defocus Incorporated Multiple Segments (DIMS) lens.

What is the DIMS lens?

The lens has a central optical zone for correcting refractive error, but the key is the multiple little micro-lenses that create constant myopic defocus surrounding the central zone extending to the mid-periphery of the lens. Here is a picture. Think of an ad on a bus window, where a meshwork of dots makes up the picture so that you can still see through the window.

Why do we want peripheral myopic defocus?

Because studies have shown that in order to control myopia progression we need to induce myopic defocus in the periphery.

Tell me about the clinical study.

The trial involved 160 Chinese children (ages 8-13), 79 of which were assigned the DIMS lens. The 2-year study results showed that the children wearing DIMS lenses had a 52% reduced rate of myopia progression compared with those who wore single-vision lenses. It’s also important to note that 21.5% of kids who wore DIMS lenses had no myopia progression over 2 years, compared with 7.4% of kids who wore single-vision lenses.

SOCIAL MEDIA ROUNDUP

The ophthalmology world lost a great one.

Legendary ophthalmologist Patricia Bath died last Thursday. She took a "special interest in combating preventable blindness in underserved populations and became the first black female doctor to patent a laser device for treating cataracts." (via)

Someone should tell this woman about daily contacts.

An NFL network reporter gets a corneal ulcer and makes a PSA for better contact lens habits.

Are your patient medication lists accurate?

A new study finds that the EHRs of nearly 1 in 3 eye care patients may contain a medication discrepancy. (via)